GlassScriptPhysician profile
Alexander D Borowsky
NPI 1891777512
$1,783.10
in general payments reported to CMS, 2019-2025
7 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what 90% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2021: $14.02 · 2023: $41.62 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,613 · Food and Beverage: $41.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,612.50 |
| Food and Beverage | $41.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,612.50 | 2025 | |
| Genentech USA, INC. | $81.18 | 2019 | |
| Roche Molecular Systems, INC. | $41.62 | 2023 | |
| Bristol Myers Squibb Company | $33.78 | 2019 | |
| Roche Diagnostics Corporation | $14.02 | 2021 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Borowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.